| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Clitorin targets EGFR (epidermal growth factor receptor), aromatase, and CD38. It acts as an inhibitor of EGFR and aromatase. By inhibiting EGFR, it may modulate cell proliferation and survival. By inhibiting aromatase, it may affect estrogen biosynthesis. Its interaction with CD38 suggests potential anti-hyperglycemic effects.
|
|---|---|
| ln Vitro |
In vitro, Clitorin has antioxidant activity in DPPH and ABTS radical scavenging assays, with IC50 values of 91.96 ppm and 250.45 ppm, respectively. It inhibits EGFR with an IC50 of 89.58 nM and aromatase with an IC50 of 77.41 nM. It shows significant interactions with CD38.
|
| ln Vivo |
In vivo activity data for Clitorin is limited. It has been studied for potential anticancer, hepatoprotective, and cardioprotective activities, making it valuable in pharmacological and nutraceutical research. Its antioxidant and anti-inflammatory properties may contribute to cellular protection against oxidative stress and regulation of inflammatory pathways.
|
| Enzyme Assay |
Clitorin is evaluated in cell-free enzymatic assays using purified EGFR and aromatase. The compound is incubated with the enzyme and a substrate, and the inhibition of enzyme activity is measured. IC50 values are determined to quantify the potency of inhibition. Its antioxidant activity is assessed using DPPH and ABTS radical scavenging assays.
|
| Cell Assay |
Clitorin is assessed in cell-based assays using cancer cell lines and other cell types. Cells are treated with Clitorin, and cell proliferation, apoptosis, and signaling pathway activation are measured. Its effects on EGFR and aromatase activity are evaluated.
|
| Animal Protocol |
Clitorin is administered in animal models to evaluate its pharmacological effects. However, specific animal study protocols are not extensively documented. It is typically formulated for in vivo administration using DMSO or other suitable vehicles.
|
| ADME/Pharmacokinetics |
Clitorin has a molecular weight of 740.66 g/mol. It has a CAS number of 55804-74-5. The compound is a flavonol glycoside. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Clitorin. The compound is for research use only and is not intended for human therapeutic use. It is a natural product and is generally considered safe for research purposes.
|
| References | |
| Additional Infomation |
According to reports, pterin is found in saxifrage, persimmon, and other organisms with available data.
Clitorin is also known as Kaempferol 3-O-β-D-glucopyranosyl(1→2)-α-L-rhamnopyranoside. It is a flavonol glycoside found in various plants. The compound is not approved for clinical use. |
| Molecular Formula |
C33H40O19
|
|---|---|
| Molecular Weight |
740.66
|
| Exact Mass |
740.22
|
| CAS # |
55804-74-5
|
| Related CAS # |
55804-74-5;
|
| PubChem CID |
11592917
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.74±0.1 g/cm3(Predicted)
|
| Boiling Point |
1054.0±65.0 °C(Predicted)
|
| Melting Point |
204-206 °C
|
| LogP |
-2
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
52
|
| Complexity |
1260
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O[C@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)C)O)O)O)O)O)O)O)O
|
| InChi Key |
WRXVPTMENPZUIZ-QEZWUOJGSA-N
|
| InChi Code |
InChI=1S/C33H40O19/c1-10-19(37)23(41)26(44)31(47-10)46-9-17-21(39)25(43)30(52-32-27(45)24(42)20(38)11(2)48-32)33(50-17)51-29-22(40)18-15(36)7-14(35)8-16(18)49-28(29)12-3-5-13(34)6-4-12/h3-8,10-11,17,19-21,23-27,30-39,41-45H,9H2,1-2H3/t10-,11-,17+,19-,20-,21+,23+,24+,25-,26+,27+,30+,31+,32-,33-/m0/s1
|
| Chemical Name |
kaempferol 3-O-(2'',6''-di-O-rhamnopyranosyl)glucopyranoside
|
| Synonyms |
Clitorin Kaempferol 3-O-(2'',6''-di-O-rhamnopyranosyl)glucopyranoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~135.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3501 mL | 6.7507 mL | 13.5015 mL | |
| 5 mM | 0.2700 mL | 1.3501 mL | 2.7003 mL | |
| 10 mM | 0.1350 mL | 0.6751 mL | 1.3501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA